Laan Wijnand, Selten Jean-Paul, Kahn René S, Huisman Anne-Margriet, Heijnen Cobi J, Grobbee Diederick E, Burger Huibert
Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Trials. 2006 Oct 23;7:31. doi: 10.1186/1745-6215-7-31.
Findings from both epidemiological and basic research point to the possibility that NSAIDS impede the deterioration in schizophrenia.
To study the efficacy of acetylsalicylic acid we will perform a randomized placebo controlled double-blind add-on trial of 80 inpatients and outpatients with schizophrenia, schizophreniform or schizoaffective disorder. Patients will be 1:1 randomized to either 3 months 1000 mg acetylsalicylic acid per day or 3 months placebo, in addition to their regular antipsychotic treatment. All patients will receive pantoprazole treatment for gastroprotection. The outcomes of this study are 3-month change in psychotic and negative symptom severity, cognitive function, and several immunological parameters. This trial may (1) yield a new (adjuvant) therapy for schizophrenia and (2) add to the knowledge on the pathogenesis of this major psychiatric disorder.
流行病学和基础研究的结果均表明，非甾体抗炎药（NSAIDS）有可能延缓精神分裂症的病情恶化。
为研究阿司匹林的疗效，我们将对80例精神分裂症、精神分裂症样或分裂情感性障碍的住院和门诊患者进行一项随机、安慰剂对照、双盲的附加试验。患者将按1:1随机分为两组，一组每天服用1000毫克阿司匹林3个月，另一组服用3个月安慰剂，同时继续接受常规抗精神病治疗。所有患者将接受泮托拉唑治疗以保护胃黏膜。本研究的结果指标为3个月时精神病性症状和阴性症状严重程度、认知功能以及多项免疫参数的变化。该试验可能（1）产生一种新的（辅助）精神分裂症治疗方法，（2）增加对这种主要精神疾病发病机制的认识。
